{
    "clinical_study": {
        "@rank": "70429", 
        "arm_group": [
            {
                "arm_group_label": "Asenapine Group", 
                "arm_group_type": "Experimental", 
                "description": "Asenapine will be given beginning on day 0 at 5 mg bid.  Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Sublingual tablets similar to the asenapine tablets."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare asenapine with placebo in the treatment of\n      depression associated with bipolar disorder, type I over eight weeks.\n\n      We hypothesize that patients will show significantly greater improvement with asenapine than\n      placebo over eight weeks of treatment."
        }, 
        "brief_title": "Asenapine for Bipolar Depression", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar Depression", 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "86 patients with an episode of major depression associated with bipolar disorder, type I\n      will be recruited by two sites for the study over fifteen months. Medication will be\n      administered in a double-blind manner.  Patients will receive asenapine (or placebo)\n      beginning on day 0 at 5 mg bid. Dose may be increased to 10 mg bid and adjusted based on\n      clinical response. Patients will be evaluated by a blinded (to treatment status) rater.\n      Patients will be seen and ratings obtained at baseline (day 0) and on days 7, 14, 28, 42,\n      and 56 (or termination from the study).  Adverse events will be evaluated as well."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meet criteria for bipolar depression based on the MINI and confirmation of a previous\n             manic or mixed episode\n\n          -  18-55 years of age\n\n          -  Female patients must be using a medically accepted means of contraception (e.g. oral\n             contraceptives, Depo-Provera, abstinence)\n\n          -  Each patient must understand the nature of the study and must provide written\n             informed consent\n\n          -  Patients must have a diagnosis of bipolar disorder, type I and currently display an\n             acute depressive episode as determined by M.I.N.I. (Sheehan et al, 1998)\n\n          -  Patients must have a baseline (day 0) MADRS score \u226526\n\n          -  Current episode of depression must have persisted for at least one month and no more\n             than six months at study entry\n\n          -  Subjects should be fluent in English\n\n        Exclusion Criteria:\n\n          -  Female patients who are either pregnant or lactating\n\n          -  Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory,\n             cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical\n             conditions\n\n          -  Any history of current or past diabetes that was treated with pharmacological\n             intervention\n\n          -  Neurological disorders including epilepsy, stroke, or severe head trauma\n\n          -  Clinically significant laboratory abnormalities, on any of the following tests: CBC\n             with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid\n             profile, fasting glucose, urinalysis, thyroid indices and EKG\n\n          -  Depression due to a general medical condition or substance-induced depression\n             (DSM-IV)\n\n          -  Mental retardation (IQ <70)\n\n          -  Meeting criteria for a mixed episode, as defined by the Diagnostic and Statistical\n             Manual of Mental Disorders, Fourth Edition (DSM-IV)\n\n          -  History of hypersensitivity to or intolerance of asenapine\n\n          -  Prior history of asenapine non-response\n\n          -  DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months\n\n          -  Judged clinically to be at suicidal risk (defined as having active suicidal ideation,\n             intent or plan, or a serious suicide attempt within 30 days, or a baseline MADRS\n             suicide score of >4)\n\n          -  Participation in a clinical trial of another investigational drug within 1 month (30\n             days) prior to study entry\n\n          -  Failure of the current depressive episode to respond to two or more pharmacological\n             interventions\n\n          -  Treatment with an injectable depot neuroleptic within less than one dosing interval\n             between depot neuroleptic injections and day 0\n\n          -  Treatment with concurrent antidepressants, mood stabilizers or anticonvulsants,\n             benzodiazepines, or psychostimulants\n\n          -  Schizophrenia or other psychotic disorders (including schizophreniform disorder,\n             schizoaffective disorder, delusional disorder, brief psychotic disorder, shared\n             psychotic disorder, psychotic disorder due to a general medical condition,\n             substance-induced psychotic disorder, psychotic disorder not otherwise specified) as\n             defined in the DSM-IV\n\n          -  Major depressive disorder, dysthymic disorder, depressive disorder not otherwise\n             specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807741", 
            "org_study_id": "2012-4181"
        }, 
        "intervention": [
            {
                "arm_group_label": "Asenapine Group", 
                "description": "Available in 5 and 10 mg.", 
                "intervention_name": "Asenapine", 
                "intervention_type": "Drug", 
                "other_name": "Saphris"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "sugar pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Asenapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bipolar Disorder", 
            "Depression"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "rummeley@ucmail.uc.edu", 
                "last_name": "Emily Rummelhoff", 
                "phone": "513-558-4295"
            }, 
            "contact_backup": {
                "email": "cal.adler@uc.edu", 
                "last_name": "Caleb M Adler, MD", 
                "phone": "513-558-3362"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45244"
                }, 
                "name": "University of Cincinnati"
            }, 
            "investigator": {
                "last_name": "Caleb M Adler, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Asenapine for Bipolar Depression", 
        "overall_contact": {
            "email": "rummeley@ucmail.uc.edu", 
            "last_name": "Emily Rummelhoff", 
            "phone": "513-558-4295"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Caleb M Adler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Montgomery-Asberg Depression Rating Scale (MADRS)will be used as a measure of efficacy reflecting change in MADRS total scores from baseline to endpoint over 8 weeks.", 
            "measure": "Change in Depression Score", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807741"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Caleb M. Adler", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "MADRS Response Rate: Defined by a \u2265 50% decrease from baseline to endpoint in MADRS total score over 8 weeks.", 
            "measure": "Change in Depression Response Rate", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "University of Cincinnati", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Louisville", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}